Biotech Firms, Billions at Risk, Lobby States to Limit Generics - By ANDREW POLLACK NYTimes.comQuicklink submitted by Susan Lee Schwartz Permalink
|This is insidious way the corporations undo any health care legislation that benefits the people. While the media gives the people celebrity gossip and dwells on disasters and sexy news, the lobbists undo everything.
"In statehouses around the country, some of the nation's biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.
"The drugs now cost patients -- or their insurers -- tens or even hundreds of thousands of dollars a year.
"Two companies, Amgen and Genentech, are proposing bills that would restrict the ability of pharmacists to substitute generic versions of biological drugs for brand name products."
The time limit for entering new comments on this Quicklink has expired.
This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.